Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BiRd vs Rd in Newly Diagnosed Multiple Myeloma
NCT02516696Phase 3Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2016
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of clarithromycin in multiple myeloma (MM), sponsored by Weill Cornell Medicine. Started Feb 2016; status: terminated.
02
Drugs
clarithromycin
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02516696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02516696.